Evidence map›Paper›PMID 41726184›Full record

ReviewFrontiers in immunology2025

Immune activation and microenvironmental crosstalk in hairy cell leukemia.

Hammad Tanzeem, Eric J Vick

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hammad TanzeemDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, United States.
Eric J VickDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hairy cell leukemia (HCL) is an indolent leukemic B-cell malignancy that typically presents with pancytopenia and splenomegaly. Many patients achieve durable initial remissions with nucleoside analogs but ultimately relapse as leukemic cells acquire or exploit resistance mechanisms. Central to this resistance is the highly specialized leukemic microenvironment, particularly within bone marrow and splenic niches where hairy cells persist despite clearance of circulating disease. These protective niches provide CXCR4- and adhesion-dependent retention signals, cytokine support, and immune-evasion mechanisms that sustain leukemic survival, promote minimal residual disease, and ultimately drive relapse. In this Mini Review, we summarize how stromal interactions, extracellular-matrix remodeling, and disrupted immune surveillance reinforce therapeutic resistance in HCL, and how BCR and MAPK signaling interact with these circuits. Further, we highlight emerging strategies, including agents that disrupt chemotaxis, adhesion, and immune checkpoints, designed to dismantle microenvironmental support and improve the depth and durability of remission in HCL.

Indexed as

Leukemia, Hairy CellTumor MicroenvironmentAnimalsHumansReceptors, CXCR4Signal TransductionReceptors, CXCR4BCR signalingCXCL12–CXCR4fibrosishairy cell leukemiaimmune-evasionleukemic microenvironmentMAPK pathwayTNF-α

Identifiers

PMID41726184
PMCPMC12917775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.